Subantimicrobial-dose doxycycline in the treatment of moderate facial acne

Parviz Toossi, Mehdi Farshchian, Farhad Malekzad, Nahid Mohtasham, Arash Kimyai-Asadi

Research output: Contribution to journalArticlepeer-review

45 Scopus citations


Background: Acne is a common inflammatory skin disorder. Oral antibiotics play a significant clinical role in treating acne. Objective: The purpose of this study was to compare the efficacy of doxycycline at antimicrobial and subantimicrobial doses for the treatment of acne. Methods: A prospective, randomized, double-blind, controlled trial was performed. One hundred patients with moderate facial acne were randomized into 2 treatment groups, one receiving a tablet containing 20 mg of doxycycline to be taken twice daily and the other receiving a tablet containing 100 mg of doxycycline and a matching placebo tablet to be taken twice daily. Results: Subantimicrobial-dose doxycycline administered twice daily for 3 months in patients with moderate inflammatory acne results in significant reduction in the number of total inflammatory lesions. There was an 84% reduction in number of papules and a 90% reduction in number of pustules with treatment. Conclusion: Subantimicrobial-dose doxycycline is an effective treatment for patients with moderate acne vulgaris.

Original languageEnglish (US)
Pages (from-to)1149-1152
Number of pages4
JournalJournal of Drugs in Dermatology
Issue number12
StatePublished - Dec 1 2008

ASJC Scopus subject areas

  • Dermatology


Dive into the research topics of 'Subantimicrobial-dose doxycycline in the treatment of moderate facial acne'. Together they form a unique fingerprint.

Cite this